Komori
Pharmarise Holdings (2796) · TargetROE Recovery

Maintaining ROE of at Least 5% and Targeting 10% in the Future

First written in FY2017. . Latest entry: FY2026.

9entries
10years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseOtherFY2017 – FY20262017: 120172018: 120182019: 020192020: 120202021: 120212022: 120222023: 120232024: 120242025: 120252026: 12026
Same theme, other companies
ROE Improvement TargetA theme 254 companies write about · 3 as a headwind · 254 as a tailwind

The whole theme swung hardest in 2020: 27 of 113 companies on the "Worse" side.

26 other companies' latest entry also says "Other".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 197 companies compared. The sentences above are computed from all 197.Comparing 200 of the theme's 258 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2026ROE RecoveryAnnual report

    「Return on equity (%) 7.2　5.1　△5.1　△5.3　1.7」

    Return on equity recovered from negative 5.3% in the previous fiscal year to 1.7%, but remained below the previous target of maintaining at least 5% and the future target of 10%.
  2. FY2025Widening negative ROEAnnual report

    「Return on equity (%) 7.3　7.2　5.1　△5.1　△5.3」

    ROE declined from △5.1% in the previous fiscal year to △5.3%, further widening the gap with the targets of maintaining ROE at 5% or higher and achieving 10% in the future.
  3. FY2024ROE turns negativeAnnual report

    「Return on equity 10.5 7.3 7.2 5.1 △ 5.1」

    ROE declined from 5.1% in the previous fiscal year to △5.1%, widening the gap with the previously stated targets of maintaining ROE at 5% or higher and achieving 10% in the future.
  4. FY2023Decline in ROEAnnual report

    「Return on equity 0.4 10.5 7.3 7.2 5.1」

    Consolidated ROE declined from 7.2% in the previous fiscal year to 5.1%.
  5. FY2022Slight decline in ROEAnnual report

    「Return on equity (%) △0.5 0.4 10.5 7.3 7.2」

    Consolidated ROE declined from 7.3% in the previous fiscal year to 7.2%.
  6. FY2021Decline in ROEAnnual report

    「Return on equity (%) 0.1　△0.5　0.4　10.5　7.3」

    Consolidated ROE declined from 10.5% in the previous fiscal year to 7.3%.
  7. FY2020Recovery of ROE to 10.5%Annual report

    「Return on equity (%) 6.9 0.1 △ 0.5 0.4 10.5」

    Consolidated ROE rose from 0.4% in the fiscal year ended May 2019 to 10.5% in the fiscal year ended May 2020.
  8. FY2018ROE target missedAnnual report

    「At the same time, we have pursued improvements in capital efficiency and set a target of maintaining return on equity (ROE) at 5% or higher and achieving 10% in the future. … ROE fell short of the target.」

    The target of maintaining ROE at 5% or higher and achieving 10% in the future was not met, due in part to impairment losses.
  9. FY2017First statedAnnual report

    「We have also set a target of maintaining return on equity (ROE) at 5% or higher and achieving 10% in the future.」

    Regarding improvements in capital efficiency, we explicitly set targets of maintaining ROE at 5% or higher and achieving 10% in the future.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
Pharmarise Holdings's next results are scheduled for 2026-09-17. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Maintaining ROE of at Least 5% and Targeting 10% in the Future | Pharmarise Holdings Corporation (2796) | Komori